Tanzania - English - Tanzania Medicinces & Medical Devices Authority

micro labs limited, india - rivaroxaban - film coated tablet - 20 mg

United States - English - NLM (National Library of Medicine)

laurus labs limited - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - - ursodiol capsules, usp are indicated for patients with radiolucent, noncalcified gallbladder stones <20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. safety of use of ursodiol capsules, usp beyond 24 months is not established. - ursodiol capsules, usp are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. - ursodiol will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. hence, patients with such stones are not candidates for ursodiol therapy. - patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for ursodiol therapy. - allergy to bile acids.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

laurus labs limited, india - atazanavir , ritonavir - tablet, film-coated - 300/100

Kenya - English - Pharmacy and Poisons Board

micro labs ltd india micro labs limited #27 race course road - levofloxacin hemihydrate - tablet - 750 mg - antibacterials for systemic use: fluoroquinolones

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - nitrofurantoin, quantity: 100 mg - capsule, hard - excipient ingredients: purified talc; magnesium stearate; lactose monohydrate; pregelatinised maize starch; titanium dioxide; sunset yellow fcf; purified water; quinoline yellow; gelatin - treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - nitrofurantoin, quantity: 50 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; purified talc; magnesium stearate; lactose monohydrate; titanium dioxide; sunset yellow fcf; purified water; quinoline yellow; gelatin - treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: silicified microcrystalline cellulose; maize starch; croscarmellose sodium; magnesium stearate - flecainide mlabs is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide mlabs should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide mlabs tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; silicified microcrystalline cellulose - flecainide mlabs is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide mlabs should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide mlabs tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - fluoxetine hydrochloride, quantity: 22.35 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; shellac; ethanol absolute; iron oxide black; butan-1-ol; isopropyl alcohol; propylene glycol; purified water; titanium dioxide; brilliant blue fcf; iron oxide yellow; gelatin; sodium lauryl sulfate - fluoxetine mlabs is indicated for the treatment of:,major depression.,obsessive compulsive disorder.,premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.,the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.

European Union - English - EMA (European Medicines Agency)

phoenix labs unlimited company - zoledronic acid, zoledronic acid monohydrate - cancer; fractures, bone - drugs for treatment of bone diseases - prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (tih);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (tih);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (tih).